유니큐어 (QURE) 주가

유니큐어(QURE)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $43.99 (-0.23%), 시가총액 $1.56B, 52주 최저~최고 $9.03 ~ $70.59.

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which

핵심 지표

• 현재가: $43.99 (-0.23%)
• 시가총액: $1.56B
• 52주 최저~최고: $9.03 ~ $70.59
• 섹터: Healthcare
• 산업: Biotechnology
• 거래소: NASDAQ

유니큐어의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.

유니큐어 재무 요약

애널리스트 전망

• 투자의견 컨센서스: 4.5385

핵심 재무비율 · 수익성 · 성장성

• PBR (주가순자산비율): 10.39
• 순이익률: 0.00%
• 영업이익률: -13.21%

자주 묻는 질문